Stratification of Clinically Vulnerable People for COVID-19 Risk Using Antibody Testing’. (STRAVINSKY Study)
This is a new 2-year study which aims to establish if antibody testing can identify who remains at greatest risk of severe COVID-19 infection after vaccinations. It is funded by National Institute for Health and Care Research (NIHR).
Lead researcher, Professor Alex Richter from University of Birmingham:
“Although the COVID-19 vaccine programme has been very successful, we know there are still some patients with weakened immune systems who remain at high risk of becoming very ill with COVID-19. The STRAVINSKY study aims to find out if an antibody test result can predict these individuals’ risk of severe COVID-19 infection. To do this, we want to recruit patients who are clinically vulnerable from all backgrounds to take part in our study. Their participation will be crucial in allowing us to build our understanding of the risk of COVID infection experienced by people with different conditions.”
To find out more, including information around eligibility to take part, head to: STRAVINSKY opens participant recruitment | British Society for Immunology
You can also join their Webinar to find out more about this study - Introducing the STRAVINSKY study: understanding who is most clinically vulnerable to COVID-19 | British Society for Immunology